Modern immune-based treatments and techniques for detecting circulating tumor DNA may be the future of successful assessment of the NAT response, and perhaps even to predict which patients are likely to develop pCR, enabling a more selective and personalized oncological approach. The gene discussed is BRD2; the disease is neoplasm.